Inotrem and the Crohn’s & Colitis Foundation Sign a R&D Collaboration Agreement to Support the Development of a New Therapeutic Approach in Inflammatory Bowel Disease (IBD)
Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today a R&D collaboration agreement with the Crohn’s & Colitis Foundation to support the development of a new therapeutic approach in IBD. The Crohn’s & Colitis Foundation is one of world’s largest and most influential non-profit organization dedicated to finding cures for Crohn’s disease and ulcerative colitis.
The objective of the R&D collaboration is to confirm the relationship between the activation of the TREM-1 pathway and the severity and progression of IBD in patients, with the ultimate intention of developing a new treatment. Inotrem will conduct this project in partnership with the Division of Gastroenterology at the Icahn School of Medicine at Mount Sinai in New York. Under the terms of the agreement, Inotrem will access data and bio-samples from Foundation’s IBD Plexus®, which is the largest IBD database in the US with data from over 25,000 patients. The project is expected to last 18 months and will be a cornerstone in the design of Inotrem’s new drug candidate first-in-human clinical study.
There are today 10 million people worldwide suffering from IBD (Crohn’s disease and ulcerative colitis), a lifelong illness for which the medical need continues to be important despite improvement over the last 30 years. Approximately 30% of patients are primarily unresponsive to existing therapies and even among responders, up to 10% will lose their response to the drug every year.
For a decade, Inotrem has been pioneering the biology of TREM-1 as a regulator of the immune response in acute and chronic inflammatory diseases. TREM-1 has been reported as a likely contributor to IBD pathophysiology, and targeting this biological pathway could offer a new treatment option for IBD patients with immune dysregulation.
Sven Zimmermann, CEO of Inotrem, says: “We are looking forward to collaborating with such a recognized and well-respected organization as The Crohn’s & Colitis Foundation. The robustness and diversity of their IBD patient database is unparalleled and will allow for in-depth analysis of TREM-1 potential as a therapeutic target in IBD patients. This agreement marks the beginning a long and fruitful partnership”.
“We are dedicated to finding cures for Crohn’s disease and ulcerative colitis and improving the quality of life for those affected by these diseases,” said Dr. Caren Heller, Chief Scientific Officer for the Crohn’s & Colitis Foundation. “We are pleased to work with Inotrem, a company that has developed a strong scientific leadership around the TREM-1 pathway, and look forward to understanding the potential ways that the TREM-1 pathway may play a role in the treatment of inflammatory bowel disease.”
Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, LR12 (nangibotide), with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr Marc Derive. Inotrem is supported by leading European and North American investors. www.inotrem.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Media contact for Inotrem
Strategies & Image (S&I)
+33 6 03 35 92 05
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Exscientia Business Update for First Quarter 202225.5.2022 23:01:00 EEST | Press release
Exscientia plc (Nasdaq: EXAI) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220525005906/en/ Recent advancements in the Company’s pipeline, collaborations, and operations, as well as financial results for the first quarter 2022, are summarised below. In addition, Exscientia will host a conference call Thursday, May 26 at 1:30 p.m. BST / 8:30 a.m. ET to provide an overview of the Company's precision medicine platform. "We started 2022 by commencing a groundbreaking collaboration with Sanofi to develop a pipeline of AI-designed medicines utilising the breadth of our end-to-end platform of AI-driven capabilities from target prioritisation, to drug engineering and patient selection. At this year's American Association of Cancer Research (AACR) Annual Meeting, we highlighted our advancements in this area, including how AI-enabled drug design can help create drug candidates for challenging targets in oncology. In addition, we sho
ArborXR Announces Strategic Collaboration with Qualcomm Technologies, Helping Companies Scale VR and AR Deployments25.5.2022 20:37:00 EEST | Press release
ArborXR announced today the company will work with Qualcomm Technologies, Inc. on an extended reality (XR) mobile device management (MDM) platform to make it easier for companies to scale virtual reality (VR) and augmented (AR) headset deployments. By working closely with original equipment manufacturer (OEM) partners and direct enterprise clients, ArborXR and Qualcomm Technologies have identified key problems that still exist in scaling a fleet of XR headsets. Companies today looking to deploy a fleet of VR or AR devices face many challenges enrolling and provisioning headsets, managing them remotely, installing apps and updates, and controlling the user experience. To solve these problems, ArborXR will provide device management software to Qualcomm Technologies’ XR customers and OEMs with large-scale deployments for use with Qualcomm Technologies’ cutting edge VR/AR hardware available. OEMs will be able to pre-install ArborXR, and ArborXR’s software will support new VR and AR referen
L&T Technology Services inaugurates Engineering R&D Centre in Poland to provide Embedded and Digital Solutions to Clients25.5.2022 20:05:00 EEST | Press release
L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a global leading pure-play engineering services company, today inaugurated its Engineering, Research and Development (ER&D) centre in Krakow, Poland, which will cater to global customers, leveraging cutting edge technologies in the Automotive, Mobility and Hi-Tech domains. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220525005835/en/ Seen in the picture (from right to left): Jagyan Mishra, Delivery Head (Europe) at LTTS, Abhishek Sinha, Chief Operating Officer and Member of the Board at LTTS, Mr. Jerzy Muzyk, Deputy Mayor of the City of Krakow, Her Excellency Nagma Mohamed Mallick, Ambassador of India to the Republic of Poland, Mr. Lukasz Słoniowski, President of the Board at Investor Support Krakow and Rajkumar Ravindranathan, Chief Business Officer at LTTS, during the inauguration of the ER&D centre. (Photo: Business Wire) The state-of-the-art centre will mark its
E-LAND Innople Chooses Rimini Street Support Services for SAP S/4 HANA25.5.2022 19:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products, and a Salesforce partner, today announced that E-LAND Innople, an IT affiliate of the South Korean conglomerate E-Land Group, has chosen Rimini Street Support for SAP. The move has drastically cut E-LAND Innople’s annual maintenance costs and freed up budget to fuel new IT technology, digital transformation, and online expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220525005081/en/ E-LAND Innople Chooses Rimini Street Support Services for SAP S/4 HANA (Graphic: Business Wire) Rimini Street Support Increases Business Agility E-LAND Innople provides IT solutions across various industries including fashion, distribution, hotels, restaurants, and construction. The company is responsible for the IT operations of E-Land Group, including ERP man
Agendia Achieves Historic Milestone of Enrolling 10,000 Patients in FLEX, the Largest-Ever Prospective, Real-World-Evidence Trial for Patients With Early Stage Breast Cancer25.5.2022 18:39:00 EEST | Press release
Agendia, Inc., a commercial-stage company focused on improving outcomes for breast cancer patients worldwide by providing physicians and patients with next-generation diagnostic and information solutions to inform optimized treatment decision-making, today announced 10,000 patients have been successfully enrolled in the FLEX Registry. Agendia’s unique FLEX Registry is a real-world, large-scale, prospective, observational breast cancer study (NCT03053193) intended to enable the discovery of novel genomic profiles to improve precision in the management of breast cancer. The FLEX Registry’s groundbreaking approach to cancer research is accelerating impactful data generation with its patient-centric design and national network of participating sites, allowing its investigator-initiated sub-studies to produce critical results that drive science forward. Six posters based on data from FLEX will be presented at ASCO 2022, one of which will be a poster discussion session. “When we developed th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom